A Major Milestone for Asia's Healthcare Landscape and the Fight Against Obesity

Innogen's GLP-1 Injection Approved for Type 2 Diabetes in China

Innogen, a Shanghai-based medical technology company, has received approval from China's National Medical Products Administration for its independently developed, human-derived, ultra-long-acting GLP-1 injection for the treatment of type 2 diabetes in adults. This marks a significant milestone for the company, making it the first in Asia and the third globally to hold independent intellectual property rights for such a drug.

The once-weekly injection offers several benefits for diabetic patients. It effectively lowers blood sugar levels, improves metabolic function, and shows promising weight-loss effects. This positions the drug as a strong competitor to imported treatments like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide.

With a half-life of up to 204 hours, Innogen's injection boasts the longest duration of action among all GLP-1 drugs currently available globally. This extended duration allows for less frequent injections, improving patient convenience and adherence to treatment.

The approval comes at a crucial time, as China grapples with the world's largest diabetes population. An estimated 148 million adults in China have diabetes, with over 60% being overweight or obese. This highlights the urgent need for effective treatment options like Innogen's GLP-1 injection.

GLP-1 therapies have gained popularity not only for their efficacy in managing diabetes but also for their potential in weight management. Studies have shown that GLP-1 drugs can lead to significant weight loss, making them a promising option for individuals struggling with obesity.

Innogen's GLP-1 injection is poised to play a significant role in addressing the growing burden of diabetes and obesity in China. With its innovative technology and promising clinical data, the drug has the potential to improve the lives of millions of patients and contribute to a healthier future.